NO20073566L - Oksyindol-derivater som agonister for 5HT4-reseptor - Google Patents

Oksyindol-derivater som agonister for 5HT4-reseptor

Info

Publication number
NO20073566L
NO20073566L NO20073566A NO20073566A NO20073566L NO 20073566 L NO20073566 L NO 20073566L NO 20073566 A NO20073566 A NO 20073566A NO 20073566 A NO20073566 A NO 20073566A NO 20073566 L NO20073566 L NO 20073566L
Authority
NO
Norway
Prior art keywords
esophageal
disease
compounds
dyspepsia
pharmaceutically acceptable
Prior art date
Application number
NO20073566A
Other languages
English (en)
Inventor
Hiroki Sone
Chikara Uchida
Kiyoshi Kawamura
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20073566L publication Critical patent/NO20073566L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Det beskrives forbindelser av formel (I) eller et farmasøytisk akseptabelt salt derav, hvor A, R1, R2, R3, R4 og R5 er hver som beskrevet heri eller et farmasøytisk akseptabelt salt, og sammensetninger inneholdende slike forbindelser og anvendelse av slike forbindelser i behandling av sykdommer mediert av 5-HT4 agonistisk aktivitet så som, men ikke begrenset til, gastroesofagal reflukssykdom, gastrointestinal sykdom, gastrisk motilitetsforstyrrelse, ikke-ulcus dyspepsi, funksjonell dyspepsi, irriterbar tarmsyndrom (IBS), forstoppelse, dyspepsi, esofagitt, gastroøsofagal sykdom, kvalme, sentralnervesystemsykdom, Alzheimers sykdom, kognitiv forstyrrelse, emesis, migrene, nevrologisk sykdom, smerte, kardiovaskulære forstyrrelser, hjertesvikt, hjertearytmi, diabetes og apnesyndrom.
NO20073566A 2005-02-22 2007-07-10 Oksyindol-derivater som agonister for 5HT4-reseptor NO20073566L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65527605P 2005-02-22 2005-02-22
PCT/IB2006/000519 WO2006090279A1 (en) 2005-02-22 2006-02-10 Oxyindole derivatives as 5ht4 receptor agonists

Publications (1)

Publication Number Publication Date
NO20073566L true NO20073566L (no) 2007-08-08

Family

ID=36579484

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073566A NO20073566L (no) 2005-02-22 2007-07-10 Oksyindol-derivater som agonister for 5HT4-reseptor

Country Status (32)

Country Link
US (2) US7589109B2 (no)
EP (1) EP1856110B1 (no)
JP (1) JP4130220B1 (no)
KR (1) KR100908547B1 (no)
CN (1) CN101522668B (no)
AP (1) AP2007004067A0 (no)
AR (1) AR053548A1 (no)
AT (1) ATE513827T1 (no)
AU (1) AU2006217534B8 (no)
BR (1) BRPI0607456A2 (no)
CA (1) CA2598536C (no)
DK (1) DK1856110T3 (no)
DO (1) DOP2006000046A (no)
EA (1) EA012615B1 (no)
ES (1) ES2366375T3 (no)
GE (1) GEP20094727B (no)
GT (1) GT200600083A (no)
HK (1) HK1135966A1 (no)
HN (1) HN2006007884A (no)
IL (1) IL184505A0 (no)
MA (1) MA29260B1 (no)
MX (1) MX2007010139A (no)
NL (1) NL1031218C2 (no)
NO (1) NO20073566L (no)
NZ (1) NZ556627A (no)
PE (1) PE20061096A1 (no)
TN (1) TNSN07319A1 (no)
TW (1) TW200640915A (no)
UA (1) UA86301C2 (no)
UY (1) UY29389A1 (no)
WO (1) WO2006090279A1 (no)
ZA (1) ZA200706420B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
NZ556627A (en) * 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
CA2611639A1 (en) * 2005-06-29 2007-01-04 Merck & Co., Inc. 4-fluoro-piperidine t-type calcium channel antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP5205971B2 (ja) * 2006-01-27 2013-06-05 宇部興産株式会社 テトラヒドロピラン化合物の製造方法
US20080051585A1 (en) * 2006-08-17 2008-02-28 Wyeth Process for the preparation of indolin-2-one derivatives useful as PR modulators
KR101697773B1 (ko) * 2008-03-10 2017-01-18 유로드러그 레버러토리즈 비. 브이. 독소필린을 포함하는 변형 방출 조성물
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
CA2750699C (en) * 2009-02-27 2015-12-29 Raqualia Pharma Inc. Oxyindole derivatives with motilin receptor agonistic activity
WO2010129757A1 (en) * 2009-05-07 2010-11-11 United Therapeutics Corporation Solid formulations of prostacyclin analogs
EP2507225B1 (en) 2009-09-14 2016-06-01 Suven Life Sciences Limited L -dihydro-2-oxoquinoline compounds as 5-ht4 receptor ligands
JP6023926B2 (ja) * 2010-02-12 2016-11-09 株式会社ＡｓｋＡｔ 認知症治療のための５−ｈｔ４受容体アゴニスト
PT2758394E (pt) 2011-09-19 2015-04-22 Suven Life Sciences Ltd Compostos heteroarilo como ligandos de recetores 5-ht4
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
ME03580B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
HUE046273T2 (hu) 2014-02-13 2020-02-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
UA126277C2 (uk) * 2015-08-12 2022-09-14 Інсайт Корпорейшн Солі інгібітору lsd1
WO2017141106A1 (en) * 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia, and hormone-related tumors
JP6999574B2 (ja) 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN114105863B (zh) * 2021-12-07 2023-11-28 江苏汉拓光学材料有限公司 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
US5552408A (en) * 1987-09-23 1996-09-03 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
JPH06506443A (ja) 1991-01-09 1994-07-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9121170D0 (en) 1991-10-05 1991-11-20 Smithkline Beecham Plc Pharmaceuticals
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5521193A (en) * 1992-06-24 1996-05-28 G. D. Searle & Co. Benzimidazole compounds
US5300512A (en) * 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5280028A (en) * 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
FR2694292B1 (fr) 1992-07-29 1994-10-21 Esteve Labor Dr Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament.
WO1994010174A1 (en) * 1992-11-05 1994-05-11 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
TW251287B (no) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9312348D0 (en) 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
US5534521A (en) * 1993-06-23 1996-07-09 G. D. Searle & Co. Benzimidazole compounds
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
GB9414139D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
DE4440675A1 (de) 1994-11-14 1996-05-15 Basf Ag Verfahren zur Herstellung von kautschukmodifizierten Formmassen mittels in den Kautschuk eingebauten, bei thermischer Zersetzung Radikale bildenden Gruppen
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
CA2303438A1 (en) * 1997-09-09 1999-03-18 Bristol-Myers Squibb Pharma Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
EP1127054A4 (en) 1998-10-29 2006-11-02 Bristol Myers Squibb Co INHIBITORS OF IMPDH ENZYME
MXPA02006137A (es) 1999-12-20 2002-12-05 Neuromed Tech Inc Bloqueadores del canal de calcio parcialmente saturados.
AU2002216314A1 (en) 2000-10-12 2002-04-22 Scott A Henderson Heterocyclic angiogenesis inhibitors
WO2002046172A2 (en) 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
ES2427166T3 (es) 2003-06-23 2013-10-29 Ono Pharmaceutical Co., Ltd. Compuesto heterocíclico tricíclico novedoso
DK1664036T3 (da) * 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
BRPI0512046A (pt) * 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
NZ556627A (en) * 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists

Also Published As

Publication number Publication date
NZ556627A (en) 2010-09-30
AR053548A1 (es) 2007-05-09
EA012615B1 (ru) 2009-10-30
GT200600083A (es) 2006-11-07
WO2006090279A1 (en) 2006-08-31
KR20070098936A (ko) 2007-10-05
CN101522668B (zh) 2012-06-06
MA29260B1 (fr) 2008-02-01
AU2006217534A8 (en) 2011-12-08
ATE513827T1 (de) 2011-07-15
TW200640915A (en) 2006-12-01
US7589109B2 (en) 2009-09-15
UA86301C2 (en) 2009-04-10
EA200701552A1 (ru) 2007-12-28
DK1856110T3 (da) 2011-08-15
ES2366375T3 (es) 2011-10-19
PE20061096A1 (es) 2006-11-09
MX2007010139A (es) 2007-09-27
GEP20094727B (en) 2009-07-10
AU2006217534A1 (en) 2006-08-31
ZA200706420B (en) 2009-04-29
NL1031218C2 (nl) 2007-01-23
AU2006217534B8 (en) 2011-12-08
EP1856110A1 (en) 2007-11-21
UY29389A1 (es) 2006-10-02
NL1031218A1 (nl) 2006-08-23
JP2008531543A (ja) 2008-08-14
JP4130220B1 (ja) 2008-08-06
EP1856110B1 (en) 2011-06-22
CN101522668A (zh) 2009-09-02
IL184505A0 (en) 2007-10-31
HK1135966A1 (en) 2010-06-18
CA2598536C (en) 2011-04-05
CA2598536A1 (en) 2006-08-31
AU2006217534B2 (en) 2011-08-11
DOP2006000046A (es) 2006-08-31
KR100908547B1 (ko) 2009-07-20
AP2007004067A0 (en) 2007-08-31
HN2006007884A (es) 2010-01-18
BRPI0607456A2 (pt) 2009-09-08
TNSN07319A1 (fr) 2008-12-31
US20060194842A1 (en) 2006-08-31
US20100173925A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
NO20073566L (no) Oksyindol-derivater som agonister for 5HT4-reseptor
NO20065160L (no) Derivater av benzimidazolon karboksylisk syre
DE602006010563D1 (de) Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
NO20061519L (no) Benzimiflazolonforbindelser som har 5HT4-reseptorantagonistisk aktivitet
UY29421A1 (es) Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones.
WO2006041985A3 (en) Thienopyridinone compounds and methods of treatment
TW201002701A (en) Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
JP2009502770A5 (no)
NO20070789L (no) Nikotinreseptoragonister for behandling av betennelsessykdommer
WO2006088954A1 (en) Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
NZ602612A (en) Novel benzamide derivatives
NO20084674L (no) 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser
NO20080354L (no) Benzofuranylderivater som 5-HT6-reseptorinhibitorer
US9382208B1 (en) Negative allosteric modulators of metabotropic glutamate receptor 2
US10538491B2 (en) 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
CU20070183A7 (es) Derivados de oxindol
DOP2005000113A (es) Drivados de acido carboxilico de bencimidazolona

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application